Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model.
The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial.
Nephrotic syndrome in multiple sclerosis patients who had undergone long-term interferon β-1b therapy.
The prediction of human response to ONO-4641, a sphingosine 1-phosphate receptor modulator, from preclinical data based on pharmacokinetic-pharmacodynamic modeling.
Takeda Pharmaceutical: New Drug Application Approval in Japan for Copaxone® Subcutaneous Injection 20 mg Syringe, a Drug for the Treatment of Multiple Sclerosis
BTG plc Close Period Update
Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases.
Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine.
Macrophage-specific chemokines induced via innate immunity by amino acid copolymers and their role in EAE.
Thrombotic microangiopathy associated with interferon beta.
2-chlorodeoxyadenosine (cladribine) induces apoptosis in human monocyte-derived dendritic cells.
Claudin-1 induced sealing of blood-brain barrier tight junctions ameliorates chronic experimental autoimmune encephalomyelitis.
GeNeuro Successful Phase 2a Clinical Study Reinforces Novel Approach to Treat Multiple Sclerosis: Patients Receiving First in Class GNbAC1 Mab Are Stable After One Year
ExtaviJect® 30G device for subcutaneous self-injection of interferon beta-1b for multiple sclerosis: a prospective European study.
Bench to bedside: tempering antigen-presenting cells in multiple sclerosis.
Mechanical environment modulates biological properties of oligodendrocyte progenitor cells.
Santhera to discontinue sale of Catena® in Canada
Physicians from Accentia and Johns Hopkins University present plans for new MS drug study for Cyrevia
Impact of sleep disorder treatment on fatigue in multiple sclerosis.
Minocycline inhibits antigen processing for presentation to human T cells: additive inhibition with chloroquine at therapeutic concentrations.
Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial.
Receptos announces issuance of composition of matter patents covering proprietary lead product candidate RPC1063
Monomethyl fumarate promotes Nrf2-dependent neuroprotection in retinal ischemia-reperfusion.
Th17 cells: A prognostic marker for MS rebound after natalizumab cessation?
Treatment satisfaction, adherence and behavioral assessment in patients de - escalating from natalizumab to interferon beta.

Pages